Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, today announced the promotion of Belinda Cowling (PhD) to Chief Scientific Officer and Leen Thielemans (PhD) to Chief Development Officer.
Belinda Cowling’s (PhD) research at the IGBMC (Strasbourg) led to the creation of Dynacure in 2016, of which she is cofounder and was scientific advisor, and transitioned to Head of Research in 2018. Belinda is responsible for the company’s R&D strategy, and leading Dynacure’s research programs in centronuclear myopathy (CNM) and other disease domains. Her focus is on translational research, drug-candidate development and expanding Dynacure’s research network with academic and industrial partners. Belinda completed her PhD in Australia at Monash University in 2008. She then moved to the IGBMC, France, to complete a postdoc in the team of Dr. Jocelyn Laporte, where she studied the normal biological function of dynamin 2. She identified down regulation of this gene as a novel therapeutic target for centronuclear myopathies1,2. She has more than 15 years’ experience in neuromuscular disease research and has published more than 28 publications in peer-reviewed journals.
Leen Thielemans (PhD) joined Dynacure in 2016 as Head of Development and established the basis of the overall development strategy for its lead program in CNM.Leenbrings with her over fifteen years of experience in pharmaceutical R&D, from drug discovery to early clinical development. She previously worked at Johnson & Johnson, 4AZA-Elbion, Movetis, and Shire where she worked on a variety of projects in bringing compounds from target identification to clinical proof-of-concept, with a track record in translational strategy and personalized medicine, including biomarkers and patient-related outcomes. Leen Thielemans is a bio-engineer from the University of Leuven and an epidemiologist with a PhD in medical sciences. She also is managing partner and co-founder of 2Bridge.
About Dynacure: www.dynacure.com
Dynacure develops new treatments for patients suffering from serious orphan disorders. Dynacure’s lead program, Dyn101, is designed to address centronuclear myopathy (CNM), a rare and debilitating disease affecting children and young adults. The Dyn101 development program targets the Dynamin 2 protein using a cEt antisense oligonucleotide candidate developed in collaboration with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.
Dynacure’s investors are AnderaPartners, Bpifrance, IdInvest, Kurma Partners and Pontifax.
1Tasfaout H, Buono S, Guo S, Kretz C, Messaddeq N, Booten S, Greenlee S, Monia BP, Cowling BS*, Laporte J*. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice. Nat Commun. 2017 Jun 7;8:15661. *equal last and corresponding authors
2Buono S, Buono S, Ross JA, Tasfaout H, Levy Y, Kretz C, Tayefeh L, Matson J, Guo S, Kessler P, Monia BP, Bitoun M, Ochala J, Laporte J, Cowling BS. Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):11066-11071.
NewCap – European Media Relations
+33(0)1 44 71 94 98
Ten Bridge Communications – U.S. Media Relations
+1 857 559 3397
Stephane van Rooijen, CEO